- Home
- All Stock List
- NSE
- Sanofi Consumer Healthcare India Ltd Share Price
Sanofi Consumer Healthcare India Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap
4,826.75
16.45 (0.34%)
-
Underperforms Index
0%
Return (1Y)
Underperformed Nifty 50 by 5.34%
-
More Volatile
1.32%
Standard Deviation (1Y)
Higher than Nifty 50 by 0.43%
-
Not so consistent
4/7
Months
underperformed Nifty 50
-
AxisDirect View
No View
5,375
4,212
News & Announcements
-
-
Sanofi Consumer posts PAT of Rs 46 crore in Q3
38 days ago
Total operating expenditure rose by 13.8% YoY to Rs 111.50 crore in Q3 FY25, due to higher finished good purchases (up 27.8% YoY) and higher other expenses (up 31.7% YoY).
Profit before tax in Q3 FY25 stood at Rs 62.80 crore, up by 2.6% from Rs 61.20 crore in Q3 FY24. Tax outgo for the period under review was Rs 17.60 crore, up by 4.1% YoY.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
The scrip slipped 1.18% to currently trade at Rs 4709.30 on the BSE.
Powered by Capital Market - Live News
-
Board of Sanofi Consumer Healthcare India recommends final dividend
21 - Feb - 2025 12:00 | 38 days ago
Sanofi Consumer Healthcare India announced that the Board of Directors of the Company at its meeting held on 20 February 2025, inter alia, have recommended the final dividend of Rs 55 per equity Share (i.e. 550%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Sanofi Consumer posts PAT of Rs 46 crore in Q3
38 days ago
Total operating expenditure rose by 13.8% YoY to Rs 111.50 crore in Q3 FY25, due to higher finished good purchases (up 27.8% YoY) and higher other expenses (up 31.7% YoY).
Profit before tax in Q3 FY25 stood at Rs 62.80 crore, up by 2.6% from Rs 61.20 crore in Q3 FY24. Tax outgo for the period under review was Rs 17.60 crore, up by 4.1% YoY.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
The scrip slipped 1.18% to currently trade at Rs 4709.30 on the BSE.
Powered by Capital Market - Live News
-
Board of Sanofi Consumer Healthcare India recommends final dividend
21 - Feb - 2025 12:00 | 38 days ago
Sanofi Consumer Healthcare India announced that the Board of Directors of the Company at its meeting held on 20 February 2025, inter alia, have recommended the final dividend of Rs 55 per equity Share (i.e. 550%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Sanofi Consumer Healthcare India standalone net profit declines 1.56% in the December 2024 quarter
38 days ago
Sanofi Consumer Healthcare India standalone net profit declines 1.56% in the December 2024 quarter
21 - Feb - 2025 12:00 | 38 days ago
Net profit of Sanofi Consumer Healthcare India declined 1.56% to Rs 44.30 crore in the quarter ended December 2024 as against Rs 45.00 crore during the previous quarter ended December 2023. Sales rose 6.75% to Rs 170.70 crore in the quarter ended December 2024 as against Rs 159.90 crore during the previous quarter ended December 2023.
For the full year,net profit rose 9.83% to Rs 181.00 crore in the year ended December 2024 as against Rs 164.80 crore during the previous year ended December 2023. Sales rose 37.89% to Rs 724.50 crore in the year ended December 2024 as against Rs 525.40 crore during the previous year ended December 2023.
Particulars Quarter Ended Year Ended Dec. 2024 Dec. 2023 % Var. Dec. 2024 Dec. 2023 % Var. Sales 170.70 159.90 7 724.50 525.40 38 OPM % 36.38 39.46 - 37.35 41.66 - PBDT 66.70 63.90 4 279.70 223.00 25 PBT 65.70 62.40 5 275.20 221.00 25 NP 44.30 45.00 -2 181.00 164.80 10 Powered by Capital Market - Live News
-
-
Sanofi Consumer posts PAT of Rs 46 crore in Q3
38 days ago
Total operating expenditure rose by 13.8% YoY to Rs 111.50 crore in Q3 FY25, due to higher finished good purchases (up 27.8% YoY) and higher other expenses (up 31.7% YoY).
Profit before tax in Q3 FY25 stood at Rs 62.80 crore, up by 2.6% from Rs 61.20 crore in Q3 FY24. Tax outgo for the period under review was Rs 17.60 crore, up by 4.1% YoY.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
The scrip slipped 1.18% to currently trade at Rs 4709.30 on the BSE.
Powered by Capital Market - Live News
-
Board of Sanofi Consumer Healthcare India recommends final dividend
21 - Feb - 2025 12:00 | 38 days ago
Sanofi Consumer Healthcare India announced that the Board of Directors of the Company at its meeting held on 20 February 2025, inter alia, have recommended the final dividend of Rs 55 per equity Share (i.e. 550%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Sanofi Consumer Healthcare India standalone net profit declines 1.56% in the December 2024 quarter
38 days ago
Sanofi Consumer Healthcare India standalone net profit declines 1.56% in the December 2024 quarter
21 - Feb - 2025 12:00 | 38 days ago
Net profit of Sanofi Consumer Healthcare India declined 1.56% to Rs 44.30 crore in the quarter ended December 2024 as against Rs 45.00 crore during the previous quarter ended December 2023. Sales rose 6.75% to Rs 170.70 crore in the quarter ended December 2024 as against Rs 159.90 crore during the previous quarter ended December 2023.
For the full year,net profit rose 9.83% to Rs 181.00 crore in the year ended December 2024 as against Rs 164.80 crore during the previous year ended December 2023. Sales rose 37.89% to Rs 724.50 crore in the year ended December 2024 as against Rs 525.40 crore during the previous year ended December 2023.
Particulars Quarter Ended Year Ended Dec. 2024 Dec. 2023 % Var. Dec. 2024 Dec. 2023 % Var. Sales 170.70 159.90 7 724.50 525.40 38 OPM % 36.38 39.46 - 37.35 41.66 - PBDT 66.70 63.90 4 279.70 223.00 25 PBT 65.70 62.40 5 275.20 221.00 25 NP 44.30 45.00 -2 181.00 164.80 10 Powered by Capital Market - Live News
-
-
Sanofi Consumer posts PAT of Rs 46 crore in Q3
38 days ago
Total operating expenditure rose by 13.8% YoY to Rs 111.50 crore in Q3 FY25, due to higher finished good purchases (up 27.8% YoY) and higher other expenses (up 31.7% YoY).
Profit before tax in Q3 FY25 stood at Rs 62.80 crore, up by 2.6% from Rs 61.20 crore in Q3 FY24. Tax outgo for the period under review was Rs 17.60 crore, up by 4.1% YoY.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
The scrip slipped 1.18% to currently trade at Rs 4709.30 on the BSE.
Powered by Capital Market - Live News
-
Board of Sanofi Consumer Healthcare India recommends final dividend
21 - Feb - 2025 12:00 | 38 days ago
Sanofi Consumer Healthcare India announced that the Board of Directors of the Company at its meeting held on 20 February 2025, inter alia, have recommended the final dividend of Rs 55 per equity Share (i.e. 550%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Sanofi Consumer posts PAT of Rs 46 crore in Q3
38 days ago
Total operating expenditure rose by 13.8% YoY to Rs 111.50 crore in Q3 FY25, due to higher finished good purchases (up 27.8% YoY) and higher other expenses (up 31.7% YoY).
Profit before tax in Q3 FY25 stood at Rs 62.80 crore, up by 2.6% from Rs 61.20 crore in Q3 FY24. Tax outgo for the period under review was Rs 17.60 crore, up by 4.1% YoY.
Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce.
The scrip slipped 1.18% to currently trade at Rs 4709.30 on the BSE.
Powered by Capital Market - Live News
-
Board of Sanofi Consumer Healthcare India recommends final dividend
21 - Feb - 2025 12:00 | 38 days ago
Sanofi Consumer Healthcare India announced that the Board of Directors of the Company at its meeting held on 20 February 2025, inter alia, have recommended the final dividend of Rs 55 per equity Share (i.e. 550%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Sanofi Consumer Healthcare India standalone net profit declines 1.56% in the December 2024 quarter
38 days ago
Sanofi Consumer Healthcare India standalone net profit declines 1.56% in the December 2024 quarter
21 - Feb - 2025 12:00 | 38 days ago
Net profit of Sanofi Consumer Healthcare India declined 1.56% to Rs 44.30 crore in the quarter ended December 2024 as against Rs 45.00 crore during the previous quarter ended December 2023. Sales rose 6.75% to Rs 170.70 crore in the quarter ended December 2024 as against Rs 159.90 crore during the previous quarter ended December 2023.
For the full year,net profit rose 9.83% to Rs 181.00 crore in the year ended December 2024 as against Rs 164.80 crore during the previous year ended December 2023. Sales rose 37.89% to Rs 724.50 crore in the year ended December 2024 as against Rs 525.40 crore during the previous year ended December 2023.
Particulars Quarter Ended Year Ended Dec. 2024 Dec. 2023 % Var. Dec. 2024 Dec. 2023 % Var. Sales 170.70 159.90 7 724.50 525.40 38 OPM % 36.38 39.46 - 37.35 41.66 - PBDT 66.70 63.90 4 279.70 223.00 25 PBT 65.70 62.40 5 275.20 221.00 25 NP 44.30 45.00 -2 181.00 164.80 10 Powered by Capital Market - Live News
Stock Trivia
FII shareholding in Sanofi Consumer Healthcare India Ltd has decreased by -9.37% since past 3 Months
Sanofi Consumer Healthcare India Ltd has the highest P/B ratio according to FY 202412 data among stocks in Pharmaceuticals Sector
FII shareholding in Sanofi Consumer Healthcare India Ltd has decreased by -9.37% since past 3 Months
MF shareholding in Sanofi Consumer Healthcare India Ltd has increased by 9.34% since past 3 Months
Sanofi Consumer Healthcare India Ltd has the highest P/B ratio according to FY 202412 data among stocks in Pharmaceuticals Sector
FII shareholding in Sanofi Consumer Healthcare India Ltd has decreased by -9.37% since past 3 Months
Sanofi Consumer Healthcare India Ltd has the highest P/B ratio according to FY 202412 data among stocks in Pharmaceuticals Sector
